Brief: Celyad Announces Key Upcoming Milestones

Celyad Oncology SA

19/11/2019 06:00

Nov 19 (Reuters) - CELYAD SA  CYAD.BR :
    * INITIATION OF THE PHASE 1 DOSE-ESCALATING STUDY CYCLE-01
EVALUATING CYAD-02, AFTER PRECONDITIONING CHEMOTHERAPY, FOR THE
TREATMENT OF AML R/R AND MDS, SCHEDULED FOR EARLY 2020.
    * COMPLETION OF THE RECRUITMENT OF THE PHASE 1 DEPLETHINK
TRIAL
EVALUATING CYAD-01 PRODUCED WITH
OPTIMAB MANUFACTURING PROCESS PLANNED FOR THE FIRST HALF OF
2020.
    * UPDATED RESULTS OF THE ALLOSHRINK DOSE INCREASE SEGMENT OF
THE
STUDY ARE EXPECTED TO BE PUBLISHED IN THE FIRST HALF OF 2020,
INCLUDING THREE ADDITIONAL PATIENTS AT DOSE LEVEL THREE (ONE
BILLION CELLS PER INFUSION)

Source text for Eikon:  ID:nBwblJ8JGa 
Further company coverage:  CYAD.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))